Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/19/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP
(NASDAQ: PPCB) Delayed: 0.61 -0.02 (3.17%)
Previous Close $0.63    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.67    P/E N/A 
Day Low $0.60    EPS $ 
Volume 160,446       

(NASDAQ: PPCB) Delayed: 0.61 -0.02 (3.17%)
Previous Close $0.63    52 Week High $ 
Open $0.66    52 Week Low $ 
Day High $0.67    P/E N/A 
Day Low $0.60    EPS $ 
Volume 160,446